关键词： Alopecia areata Autoimmune disease Autoinflammatory Baricitinib CANDLE syndrome Gene expression profiling Interferon gamma JAK inhibitor

Mesh ： Alopecia Areata / drug therapy enzymology Animals Azetidines / therapeutic use Disease Models, Animal Interferons / metabolism Janus Kinases / antagonists & inhibitors Male Mice, Inbred C3H Protein Kinase Inhibitors / therapeutic use Purines Pyrazoles Sulfonamides / therapeutic use

来  源：   DOI：10.1016/j.ebiom.2015.02.015   PDF(Sci-hub)

Abstract：
BACKGROUND: Alopecia areata (AA) is an autoimmune disease resulting in hair loss with devastating psychosocial consequences. Despite its high prevalence, there are no FDA-approved treatments for AA. Prior studies have identified a prominent interferon signature in AA, which signals through JAK molecules.
METHODS: A patient with AA was enrolled in a clinical trial to examine the efficacy of baricitinib, a JAK1/2 inhibitor, to treat concomitant CANDLE syndrome. In vivo, preclinical studies were conducted using the C3H/HeJ AA mouse model to assess the mechanism of clinical improvement by baricitinib.
RESULTS: The patient exhibited a striking improvement of his AA on baricitinib over several months. In vivo studies using the C3H/HeJ mouse model demonstrated a strong correlation between resolution of the interferon signature and clinical improvement during baricitinib treatment.
CONCLUSIONS: Baricitinib may be an effective treatment for AA and warrants further investigation in clinical trials.
摘要：
暂无翻译
公众号